{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:33:56Z","timestamp":1762432436963,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfeicoamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001","403193\/2022-2"],"award-info":[{"award-number":["001","403193\/2022-2"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["001","403193\/2022-2"],"award-info":[{"award-number":["001","403193\/2022-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The emergence of COVID-19 caused by SARS-CoV-2 prompted an unprecedented global response to develop vaccines at an accelerated pace. Messenger RNA (mRNA) and adenovirus vector vaccines emerged as the frontrunners in global immunization efforts, significantly reducing hospitalization, severity, and mortality, supplemented by inactivated virus-based vaccines in developing countries. However, concerns regarding adverse effects, including allergic reactions, have been raised. This study aimed to investigate the adverse effects following COVID-19 vaccination, particularly in atopic and non-atopic individuals. A cohort of 305 volunteers receiving BNT162, ChAdOx1, or CoronaVac vaccines were assessed based on a Skin Prick Test (SPT), specific IgE levels, and clinical history of asthma and rhinitis. Adverse effects were self-reported and scored across the different vaccination shots. The results indicated a notable presence of mild adverse effects following the first and third doses, regardless of vaccine type. ChAdOx1 recipients experienced more adverse effects compared to those receiving BNT162 and CoronaVac, including headaches, muscle pain, fever, chills, nausea, and flu-like symptoms. Atopic individuals receiving ChAdOx1 reported more adverse effects, such as muscle pain, fever, and chills, compared to non-atopic individuals. Conversely, headaches were more frequently reported in non-atopic individuals receiving BNT162 compared to atopic individuals. No anaphylaxis or allergic reactions were reported, indicating valuable evidence supporting the safety of COVID-19 vaccination in individuals with respiratory allergies. This study highlights the importance of understanding vaccine-related adverse effects, particularly in vulnerable populations, to inform vaccination strategies and address safety concerns in global immunization campaigns.<\/jats:p>","DOI":"10.3390\/vaccines12040408","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T03:34:37Z","timestamp":1712892877000},"page":"408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct Adverse Reactions to mRNA, Inactivated Virus, and Adenovirus Vector COVID-19 Vaccines: Insights from a Cohort Study on Atopic and Non-Atopic Subjects in Brazil"],"prefix":"10.3390","volume":"12","author":[{"given":"Laura Alves Ribeiro","family":"Oliveira","sequence":"first","affiliation":[{"name":"Laboratory of Allergy and Clinical Immunology, Institute of Biomedical Sciences, Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia 38405-317, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1370-0714","authenticated-orcid":false,"given":"Alessandro Sousa","family":"Correa","sequence":"additional","affiliation":[{"name":"Laboratory of Allergy and Clinical Immunology, Institute of Biomedical Sciences, Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia 38405-317, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Alves","family":"de Jesus","sequence":"additional","affiliation":[{"name":"Laboratory of Allergy and Clinical Immunology, Institute of Biomedical Sciences, Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia 38405-317, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Junior Sordi","family":"Bortolini","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Immunology, Health and Sports Sciences Center, Federal University of Acre, Rio Branco 69920-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto Akio","family":"Taketomi","sequence":"additional","affiliation":[{"name":"Laboratory of Allergy and Clinical Immunology, Institute of Biomedical Sciences, Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia 38405-317, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-6353","authenticated-orcid":false,"given":"Rafael de Oliveira","family":"Resende","sequence":"additional","affiliation":[{"name":"Laboratory of Allergy and Clinical Immunology, Institute of Biomedical Sciences, Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia 38405-317, Brazil"},{"name":"Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro 21040-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3389\/fimmu.2020.579250","article-title":"Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines","volume":"11","author":"Flanagan","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102206","DOI":"10.1016\/j.coi.2022.102206","article-title":"Accelerating clinical trial development in vaccinology: COVID-19 and beyond","volume":"76","author":"Corey","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/all.14868","article-title":"Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe","volume":"77","author":"Wagner","year":"2022","journal-title":"Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Eterafi, M., Fouladi, N., Golizadeh, M., Shaker, H., Matin, S., and Safarzadeh, E. (2024). Reported side-effects following Oxford\/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0296669"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109968","DOI":"10.1016\/j.intimp.2023.109968","article-title":"Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2","volume":"117","author":"Firouzabadi","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/d41586-021-03686-x","article-title":"How COVID vaccines shaped 2021 in eight powerful charts","volume":"600","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: A mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81477","DOI":"10.7554\/eLife.81477","article-title":"Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial","volume":"11","author":"Pacheco","year":"2022","journal-title":"eLife"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10125","DOI":"10.1038\/s41598-022-14283-x","article-title":"Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19","volume":"12","author":"Ortega","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_14","first-page":"Cd015477","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Ghosn","year":"2022","journal-title":"Cochrane. Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40259-022-00536-8","article-title":"Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management","volume":"36","author":"Luxi","year":"2022","journal-title":"BioDrugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1016\/j.vaccine.2021.06.058","article-title":"Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration","volume":"39","author":"Desai","year":"2021","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00431-022-04643-0","article-title":"Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5\u201311 years and comparison with individuals aged 12\u201315 years: An observational and historical cohort study","volume":"182","author":"Yoshida","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"878081","DOI":"10.3389\/fpubh.2022.878081","article-title":"Allergic Reactions After the Administration of COVID-19 Vaccines","volume":"10","author":"Bian","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nittner-Marszalska, M., Rosiek-Biegus, M., Kope\u0107, A., Paw\u0142owicz, R., Kosi\u0144ska, M., \u0141ata, A., and Szenborn, L. (2021). Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals. Vaccine, 9.","DOI":"10.3390\/vaccines9060553"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2045-9912.326003","article-title":"Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac\u00ae): A case report","volume":"12","author":"Uzer","year":"2022","journal-title":"Med. Gas Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","article-title":"Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003","volume":"113","author":"Johansson","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"691964","DOI":"10.3389\/fimmu.2021.691964","article-title":"Local Respiratory Allergy: From Rhinitis Phenotype to Disease Spectrum","volume":"12","author":"Salas","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1111\/all.14582","article-title":"Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma","volume":"75","author":"Breiteneder","year":"2020","journal-title":"Allergy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12016-020-08787-5","article-title":"Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches","volume":"60","author":"Mersha","year":"2021","journal-title":"Clin. Rev. Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2022.10.010","article-title":"Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors","volume":"151","author":"Wang","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clim.2010.02.019","article-title":"Antibody and cytokine responses to house dust mite allergens and Toxoplasma gondii antigens in atopic and non-atopic Brazilian subjects","volume":"136","author":"Fernandes","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/eji.202249951","article-title":"IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination","volume":"52","author":"Meltendorf","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Correa, A.S., Miranda, J.S., Oliveira, L.A.R., Moreira, P.F.S., Vieira, F.A.M., Cunha-Junior, J.P., Resende, R.O., and Taketomi, E.A. (2023). Identification of carboxymethyl (CM)-binding proteins derived from Lolium multiflorum pollen extract and antibody reactivity in Brazilian allergic patients. Braz. J. Med. Biol., 56.","DOI":"10.1590\/1414-431x2023e12957"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Resende, R.O., Ynoue, L.H., Miranda, J.S., de Almeida, K.C., Silva, D.A.O., Sopelete, M.C., Alves, R., Gennari-Cardoso, M.L., and Taketomi, E.A. (2019). IgE, IgG1, and IgG4 Reactivity to Dermatophagoides pteronyssinus Glycosylated Extract in Allergic Patients. BioMed Res. Int., 2019.","DOI":"10.1155\/2019\/9840890"},{"key":"ref_31","first-page":"1445","article-title":"Responses of IgE, IgG1, and IgG4 to concanavalin A-binding Blomia tropicalis antigens in allergic patients","volume":"39","author":"Almeida","year":"2006","journal-title":"Braz. J. Med. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11882-023-01089-8","article-title":"The Relationship of Parasite Allergens to Allergic Diseases","volume":"23","author":"Caraballo","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1001\/jama.2020.20590","article-title":"Answering Key Questions About COVID-19 Vaccines","volume":"324","author":"Goodman","year":"2020","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijid.2021.04.047","article-title":"Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers","volume":"106","author":"Kadali","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"937794","DOI":"10.3389\/fpubh.2022.937794","article-title":"Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study","volume":"10","author":"Yesuf","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomized, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Caminati, M., Guarnieri, G., Batani, V., Scarpieri, E., Finocchiaro, A., Chieco-Bianchi, F., Senna, G., and Vianello, A. (2021). COVID-19 vaccination in patients with severe asthma on biologic treatment: Safety, tolerability, and impact on disease control. Vaccine, 9.","DOI":"10.3390\/vaccines9080853"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Atayik, E., and Aytek\u0456n, G.J.M. (2022). Are allergic diseases a risk factor for systemic side effects after COVID-19 vaccines?. medRxiv, 22269704.","DOI":"10.1101\/2022.01.23.22269704"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-022-02054-1","article-title":"Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases","volume":"23","author":"Cao","year":"2022","journal-title":"Respir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/all.14711","article-title":"Allergic reactions to the first COVID-19 vaccine: A potential role of Polyethylene glycol","volume":"76","author":"Cabanillas","year":"2021","journal-title":"Allergy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/all.14739","article-title":"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines","volume":"76","author":"Sokolowska","year":"2021","journal-title":"Allergy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13223-022-00665-3","article-title":"AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy","volume":"18","author":"Ali","year":"2022","journal-title":"Allergy Asthma Clin. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/4\/408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:26:50Z","timestamp":1760106410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/4\/408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["vaccines12040408"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12040408","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,4,12]]}}}